On Friday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened lower -7.99% from the last session, before settling in for the closing price of $15.9. Price fluctuations for NTLA have ranged from $5.90 to $28.25 over the past 52 weeks.
Healthcare Sector giant saw their annual sales slid by -20.04% over the last five years. Company’s average yearly earnings per share was noted 23.97% at the time writing. With a float of $109.90 million, this company’s outstanding shares have now reached $115.79 million.
Intellia Therapeutics Inc (NTLA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 5.12%, while institutional ownership is 88.18%. The most recent insider transaction that took place on Jan 05 ’26, was worth 314,485. In this transaction President and CEO of this company sold 34,146 shares at a rate of $9.21, taking the stock ownership to the 1,013,339 shares. Before that another transaction happened on Jan 05 ’26, when Company’s EVP, Chief Scientific Officer sold 8,508 for $9.21, making the entire transaction worth $78,359. This insider now owns 98,533 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -1.27 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.32) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.85% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 6.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.27, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -3.62 in one year’s time.
